Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly H Skelton

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 22, 2004
Spontaneous withdrawal from the triazolobenzodiazepine alprazolam increases cortical corticotropin-releasing factor mRNA expressionKelly H Skelton, Charles B Nemeroff, Michael J Owens
Human Psychopharmacology|October 31, 2002
Are CRF receptor antagonists potential antidepressants?Donna O'Brien, Kelly H Skelton, Michael J Owens, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2003
The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systemsMichelle L Gilmor, Kelly H Skelton, Charles B Nemeroff, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 23, 2003
The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stressDavid A Gutman, Michael J Owens, Kelly H Skelton, et al.
Psychopharmacology|February 14, 2007
The CRF1 receptor antagonist R121919 attenuates the neuroendocrine and behavioral effects of precipitated lorazepam withdrawalKelly H Skelton, David A Gutman, K V Thrivikraman, et al.
European Journal of Pharmacology|July 6, 2007
The CRF1 receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawalKelly H Skelton, Dana Oren, David A Gutman, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 22, 2004
Spontaneous withdrawal from the triazolobenzodiazepine alprazolam increases cortical corticotropin-releasing factor mRNA expressionKelly H Skelton, Charles B Nemeroff, Michael J Owens
Human Psychopharmacology|October 31, 2002
Are CRF receptor antagonists potential antidepressants?Donna O'Brien, Kelly H Skelton, Michael J Owens, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2003
The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systemsMichelle L Gilmor, Kelly H Skelton, Charles B Nemeroff, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 23, 2003
The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stressDavid A Gutman, Michael J Owens, Kelly H Skelton, et al.
Psychopharmacology|February 14, 2007
The CRF1 receptor antagonist R121919 attenuates the neuroendocrine and behavioral effects of precipitated lorazepam withdrawalKelly H Skelton, David A Gutman, K V Thrivikraman, et al.
European Journal of Pharmacology|July 6, 2007
The CRF1 receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawalKelly H Skelton, Dana Oren, David A Gutman, et al.
Pageof 1